Tyra Biosciences Inc TYRA.OQ TYRA.O is expected to show no change in quarterly revenue when it reports results on August 5 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Tyra Biosciences Inc is for a loss of 53 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Tyra Biosciences Inc is $30.00, about 63.6% above its last closing price of $10.93
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.49 | -0.49 | -0.47 | Beat | 4 |
Dec. 31 2025 | -0.42 | -0.48 | -0.43 | Beat | 10.5 |
Sep. 30 2024 | -0.39 | -0.40 | -0.41 | Missed | -2.8 |
Jun. 30 2024 | -0.39 | -0.41 | -0.32 | Beat | 21.6 |
Mar. 31 2024 | -0.46 | -0.46 | -0.35 | Beat | 23.1 |
Dec. 31 2023 | -0.43 | -0.48 | -0.53 | Missed | -10.3 |
Sep. 30 2023 | -0.37 | -0.35 | -0.49 | Missed | -38.9 |
Jun. 30 2023 | -0.32 | -0.34 | -0.31 | Beat | 9.8 |
This summary was machine generated August 1 at 21:29 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)